Home

DANIEL M JUNIUS

CIK 1094159 · Chief Executive Officer · last filed 2026-05-14

DANIEL M JUNIUS is a Chief Executive Officer who has filed 126 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for IDXX, was dated May 14, 2026. Across all open-market trades the lifetime net is −$12.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.94M

Companies

4

Total Filings

126

Lifetime Open-Market Net

-$12.12M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IDXX Director 3,561 $545.16 $1.94M -$8.93M 60 2026-05-14
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director 985 $15.70 $15.5K $214.1K 17 2024-05-01
ImmunoGen, Inc. (IMGN) Delisted Director 209,987 $31.23 $6.56M -$3.40M 46 2018-03-16
Vitae Pharmaceuticals, Inc (VTAE) Delisted Director — — — $0 2 2016-10-25

Recent Filings

126 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-14 IDXX Grant (A) — $0 EDGAR
2026-05-11 IDXX Exer (M) +257 $0 EDGAR
2025-05-14 IDXX Mixed — -$650.9K EDGAR
2025-05-13 IDXX Notice (144) −2,683 -$1.36M EDGAR
2025-05-08 IDXX Mixed +262 $0 EDGAR
2024-05-08 IDXX Grant (A) — $0 EDGAR
2024-05-01 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2024-04-02 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) +5,209 $15.6K EDGAR
2024-02-01 IDXX Grant (A) +14 $7.3K EDGAR
2023-11-01 IDXX Grant (A) +19 $7.5K EDGAR
Showing 1–10 of 126
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.